Cerus Co. (NASDAQ:CERS) Shares Sold by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC decreased its holdings in Cerus Co. (NASDAQ:CERS) by 11.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 59,740 shares of the biotechnology company’s stock after selling 7,860 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Cerus were worth $92,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Creative Planning boosted its position in shares of Cerus by 51.3% in the 3rd quarter. Creative Planning now owns 24,809 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 8,411 shares in the last quarter. PCA Investment Advisory Services Inc. acquired a new stake in shares of Cerus in the 4th quarter worth $46,000. IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its position in Cerus by 38.4% during the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 35,074 shares of the biotechnology company’s stock worth $61,000 after acquiring an additional 9,737 shares during the period. Intech Investment Management LLC acquired a new stake in Cerus during the 3rd quarter worth about $71,000. Finally, SG Americas Securities LLC acquired a new stake in Cerus during the 3rd quarter worth about $121,000. Institutional investors and hedge funds own 78.37% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Stifel Nicolaus lowered their price target on Cerus from $6.00 to $3.00 and set a “buy” rating for the company in a research report on Thursday, October 17th.

Insider Buying and Selling at Cerus

In other Cerus news, Director Eric Bjerkholt sold 20,000 shares of Cerus stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $1.78, for a total transaction of $35,600.00. Following the completion of the transaction, the director now owns 162,133 shares in the company, valued at approximately $288,596.74. This trade represents a 10.98 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 3.40% of the company’s stock.

Cerus Stock Performance

Shares of CERS opened at $1.80 on Friday. The stock has a 50-day moving average of $1.74 and a two-hundred day moving average of $1.85. Cerus Co. has a one year low of $1.38 and a one year high of $2.59. The company has a debt-to-equity ratio of 1.19, a quick ratio of 1.92 and a current ratio of 2.59. The stock has a market cap of $334.29 million, a P/E ratio of -16.36 and a beta of 1.29.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.